Jonathan Mandelbaum

Biotech VC | @OrbiMed | Classic Rocker | Toronto Ex-Pat | Wannabe New-Yorker | World Traveler | Tweets are my own opinion

[Jonathan Mandelbaum @biotechbaumer]

https://t.co/0BpoWP1150

[Jonathan Mandelbaum @biotechbaumer]

Mirador 💪💪 https://t.co/vayXWlQTEf

[Jonathan Mandelbaum @biotechbaumer]

https://t.co/dVi0R9zbjo

[Disc Medicine @DiscMedicine]

We're excited to announce positive feedback from our end-of-Phase 2 meeting with the FDA, supporting the development path forward for bitopertin in #EPP and highlighting the potential for accelerated approval. Join us for our webcast at 8am ET: https://t.co/qiARsEHt3x

[Jonathan Mandelbaum @biotechbaumer]

https://t.co/KzaYMxRHQX.

[Ben Fidler @BentheFidler]

With $115M more, Triveni accelerates immune drug work https://t.co/P7TkrkIDYM by @gwendolynawu #biotech #startups $REGN $APGE

[Jonathan Mandelbaum @biotechbaumer]

@bmgallagherjr Baba O-Riley is up there

[Adam Feuerstein ✡️ @adamfeuerstein]

Prometheus team launches new startup with $400 million to tackle immune-driven disorders https://t.co/5WKoy2SXKZ via @ADeAngelis_bio

[Ben Fidler @BentheFidler]

Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off https://t.co/pYATeNPqbh by @gwendolynawu $RXDX $MRK

[Disc Medicine @DiscMedicine]

This #RareDiseaseDay, join us in raising awareness for the 300 million people globally living with a rare disease, including those with erythropoietic porphyria (#EPP) and other hematologic disorders.

[Jonathan Mandelbaum @biotechbaumer]

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders https://t.co/2tnKQMbFGp

[OrbiMed @OrbiMed]

OrbiMed is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. Read more here: https://t.co/XXMAi54T9G

[OrbiMed @OrbiMed]

OrbiMed portfolio company Aliada Therapeutics, along with Chiesi Global Rare Diseases, announces a co-development agreement to advance Aliada's blood-brain barrier-crossing platform technology in lysosomal storage disorders. Read more: https://t.co/0UkUPfW4Rq

[The Tragically Hip @thehipofficial]

24 years ago today we played Woodstock ‘99. Here’s how we opened our set, with “Grace, Too”...

[Disc Medicine @DiscMedicine]

In data presented at #EHA2023, Disc announced initial positive results from BEACON, our Phase 2 clinical trial for bitopertin in #EPP. Read more: https://t.co/dokeoBCkxE

[Disc Medicine @DiscMedicine]

Please join Disc as we host a virtual KOL investor event on Tuesday, April 25, 2023, at 1:00 pm ET / 10:00 am PT to provide an overview of our lead indication #EPP, a rare, severe disease caused by mutations in the heme biosynthesis pathway.
https://t.co/qf5j0NjB6f

[Disc Medicine @DiscMedicine]

Disc is pleased to announce the initiation of our Phase 1b/2 clinical study of DISC-0974 in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with #anemia. Thanks to our fantastic R&D team in getting this study off the ground!
https://t.co/1qjgoV0Qpx

[Don Nicholson @DonWNicholson]

Exciting year ahead for @DiscMedicine. Excellent article from @endpts on today's news:
With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital - https://t.co/2arIC5AeEf

[Jonathan Mandelbaum @biotechbaumer]

@michael_gilman So good!

[Brian Gallagher, Jr. @bmgallagherjr]

Given yesterdays news of $AMGN buying $HZN for $28B I’ve been asked to give color to the Tepezza history by a few people in a Tweet Thread. So here it goes. It’s my fist so be kind.